MEDP vs ORIC
MEDP: Medpace is a specialized, full-service clinical contract research organization that helps biopharmaceutical and medical device companies accelerate the development of new therapies through every phase of clinical trials. ORIC: ORIC Pharmaceuticals is a clinical-stage oncology company developing targeted therapies for hard-to-treat cancers through precision medicine approaches.
Side-by-side fundamentals
| Metric | MEDP | ORIC | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $528.12 | $10.75 | |
| Market cap as of 2026-07-23 | $15.0B | $1.1B | |
| P/E as of 2026-07-23 | 32.69 | n/a | |
| PEG as of 2026-07-23 | 2.71 | n/a | |
| Net margin as of 2026-07-23 | +17.2% | n/a | |
| Gross margin as of 2026-07-23 | +29.1% | n/a | |
| Operating margin as of 2026-07-23 | +21.0% | n/a | |
| ROE as of 2026-07-23 | +120.9% | -35.3% | MEDP higher |
| ROA as of 2026-07-23 | +24.8% | -33.3% | MEDP higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +24.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +20.1% | n/a | |
| Beta as of 2026-07-23 | 1.15 | 0.94 | |
| 1-year return as of 2026-07-22 close | +10.5% | -3.6% | MEDP higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.